arrow
J

Ji Yun Lee

Seoul National University Hospital
H指数:29
被引数:2,881
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital

在三级教学医院中针对老年癌症患者开展肿瘤-老年干预模型的可行性初步研究

2026-01-010
OA
Validating the Korean Geriatric Assessment Tool in Elderly Multiple Myeloma Patients: A Multicenter Study

韩国老年评估工具在老年多发性骨髓瘤患者中的验证:一项多中心研究

2026-01-011
OAAI
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma

早期生长反应1作为PD-L1表达和免疫逃逸的关键调节因子在结外NK/T细胞淋巴瘤中的作用

2025-06-130
OAAI
Real-World Comparison of Carfilzomib, Lenalidomide, and Dexamethasone Versus Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: KMM2004 Study

真实世界比较卡非佐米、来那度胺和地塞米松与伊沙佐米、来那度胺和地塞米松在复发/难治性多发性骨髓瘤患者中的应用:KMM2004研究

2025-06-040
PRE
Association of TP53 Mutation Status and Sex with Clinical Outcome in Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Retrospective Cohort Study

TP53突变状态与性别对接受免疫检查点抑制剂治疗的非小细胞肺癌患者临床结局的影响:一项回顾性队列研究

2025-01-151
OA
Real-World Efficacy and Safety of Teclistamab for Patients with Released or Refractory Multiple Myeloma: Korean, Nationwide, Retrospective Analysis of an Named Patient Program

托西卡玛单抗在复发或难治性多发性骨髓瘤患者中的真实世界疗效与安全性:韩国全国性回顾性分析(基于指定患者用药计划)

BLOOD
IF23.1
2024-11-050
PRE
Ropeginterferon in Low-Risk Patients with Polycythemia Vera

罗普干扰素在低风险真性红细胞增多症患者中的应用

BLOOD
IF23.1
2024-11-050
PRE
Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015)

白消安加美法仑与大剂量美法仑作为具有高风险特征的多发性骨髓瘤自体干细胞移植的预处理方案 (KMM 2015)

2023-07-012
PRE